差差分化的甲状腺癌的预后:系统性审查和元分析
Ji Young Kim1, Jae Kyung Myung2, Soyun Kim3
1Department of Nuclear Medicine, Hanyang University Medical Center, Hanyang University College of Medicine, Seoul, Korea.
Endocrinology and metabolism (Seoul, Korea)
|June 26, 2024
概括
这一元分析显示,差分化甲状腺癌 (PDTC) 的5年总生存率为73.8%. 甲状腺外延伸 (ETE) 是一个重要的预后因素,影响PDTC患者的生存结果.
科学领域:
- 内分泌学 在内分泌学.
- 在瘤学瘤学.
- 病理学 病理学 病理学
背景情况:
- 差差分化的甲状腺癌 (PDTC) 是罕见但具有攻击性,对甲状腺癌死亡率有显著的贡献.
- 对PDTC的预后因素和临床结果仍然不完全理解.
- 本研究评估了治疗治疗后PDTC患者的临床结果.
研究的目的:
- 评估PDTC患者的临床结果,特别是5年无病生存期 (DFS) 和整体生存期 (OS).
- 确定影响PDTC生存的预后因素.
- 为了巩固PDTC的各种组织学标准的证据.
主要方法:
- 一项对20项回顾性研究 (2007-2023) 的系统元分析,涉及1294名接受初始手术的PDTC患者.
- 包括使用第三,第四,第五世卫组织和MSKCC组织学标准进行PDTC诊断的研究.
- 使用随机效应模型和预后因素评估的元回归进行聚合比例分析.
主要成果:
- 合并后的5年DFS为49.4% (95% CI,42.3-56.4),而5年的OS为73.8% (95% CI,66.5-79.9).
- 对于DFS (58%) 和OS (55%) 均观察到适度的异质性.
- 超回归确定了甲状腺外延伸 (ETE) 作为OS的显著预后因素.
结论:
- 分析强调了PDTC结果在各种组织学分类中的适度异质性.
- 甲状腺外延伸 (ETE) 显著影响PDTC患者的整体存活期 (OS).
- 这些发现强调了在PDTC的预后评估中考虑ETE的重要性.
相关概念视频
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Cancer Survival Analysis
342
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
342


